Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hate to be the bearer of bad news, but do the math.
A financing now at $.0022, will be a billion shares to raise $2,200,000 dollars. How long will that last, and that is without a discount.
Think if there are free warrants too. Please sell this company, for a dime maybe.
Gene is clueless.
He is in way over his head.
He ought to just sell this pig for a dollar a share,.to someone who can market it, because he obviously can't.
I am down 12 grand, and the most I paid was .04 cents, my average is .02.
I wonder how many shares are out now, and when the next reverse split is.
I am really not trying to bash this stock, but the only thing that happens here is dilution.
Please prove me wrong and give me hope!
I am guessing, just like the DcVax-L paper was ignored and basically buried in the U.S.
Comment of Meindert Boysen, director of the centre for health technology evaluation at NICE.
http://www.irishnews.com/magazine/science/2018/08/28/news/-breakthrough-personalised-cancer-treatment-rejected-for-nhs-use-1418127/
The National Institute for Health and Care Excellence (Nice) published draft guidance stating that axicabtagene ciloleucel, also known as Yescarta, is not recommended for NHS use for patients with aggressive sub-types of non-Hodgkin lymphoma.
Quote:
“But Nice said that there is no direct data to compare it with the current standard treatment of salvage chemotherapy.
It said that cost of axicabtagene ciloleucel was also too high for it to be considered a cost-effective use of NHS resources.
The health body also considered whether the treatment should be made available to patients through the Cancer Drugs Fund, but concluded that the therapy would not be cost-effective under the scheme.
Meindert Boysen, director of the centre for health technology evaluation at Nice, said: “CAR-T is an exciting innovation in very difficult-to-treat cancers, with a promise of cure for some patients.
“We have been working with the companies involved, and with NHS England, with the aim of ensuring that patients in England are among the first to have access to these new treatments in Europe.
“Although promising, there is still much more we need to know about CAR-T, and unfortunately, in this case, we are not able to recommend axicabtagene ciloleucel for use in the NHS in England at the cost per patient set by Kite Pharma.”
Hat tip: Lykiri
Not so fast on the EU approvals....
? UK drug price watch dog NICE says that Gilead is trying to price its groundbreaking CAR-T drug Yescarta too high. The price overseers spurned the drug a day after European regulators provided a thumbs-up on marketing. But it won’t be available on the NHS unless the big biotech is ready to drop the price lower. Novartis’ rival Kymriah — also approved Monday — is under review now.
https://endpts.com/arenas-diet-drug-castoff-deemed-safe-in-study-uk-price-overseers-say-breakthrough-car-t-yescarta-is-too-expensive/?utm_medium=email&utm_campaign=553%20Tue%2082818%20Genentech%20pens%20a%20new%20Cinderella%20story%20for%20biotech%20partner%20Bristol-Myers%20taps%20commercial%20player%20for%20top%20sales%20job&utm_content=553%20Tue%2082818%20Genentech%20pens%20a%20new%20Cinderella%20story%20for%20biotech%20partner%20Bristol-Myers%20taps%20commercial%20player%20for%20top%20sales%20job+CID_9ad87df369fa4d514e63bf9618d2812d&utm_source=ENDPOINTS%20emails&utm_term=Arenas%20diet%20drug%20castoff%20deemed%20safe%20in%20study%20UK%20price%20overseers%20say%20breakthrough%20CAR-T%20Yescarta%20is%20too%20expensive
NICE and Yescarta…
? UK drug price watch dog NICE says that Gilead is trying to price its groundbreaking CAR-T drug Yescarta too high. The price overseers spurned the drug a day after European regulators provided a thumbs-up on marketing. But it won’t be available on the NHS unless the big biotech is ready to drop the price lower. Novartis’ rival Kymriah — also approved Monday — is under review now.
https://endpts.com/arenas-diet-drug-castoff-deemed-safe-in-study-uk-price-overseers-say-breakthrough-car-t-yescarta-is-too-expensive/?utm_medium=email&utm_campaign=553%20Tue%2082818%20Genentech%20pens%20a%20new%20Cinderella%20story%20for%20biotech%20partner%20Bristol-Myers%20taps%20commercial%20player%20for%20top%20sales%20job&utm_content=553%20Tue%2082818%20Genentech%20pens%20a%20new%20Cinderella%20story%20for%20biotech%20partner%20Bristol-Myers%20taps%20commercial%20player%20for%20top%20sales%20job+CID_9ad87df369fa4d514e63bf9618d2812d&utm_source=ENDPOINTS%20emails&utm_term=Arenas%20diet%20drug%20castoff%20deemed%20safe%20in%20study%20UK%20price%20overseers%20say%20breakthrough%20CAR-T%20Yescarta%20is%20too%20expensive
Maybe, he wants to wait and sell for what he thinks the company is worth.
I have warrants in another company, that I got for free in a $2 raise.
The stock is now 14 dollars, but I do not sell them because I think the company will double or be bought out before they expire.
Maybe he thinks the same. Had he sold them, you would probably be whining because he sold them, and therefore he believes the stock is going to zero.
He is in a no-win situation with you.
I guess it means he is not ready to sell at these prices.....
So why convert?
Would you care to elaborate on this statement?
The question for me is will we get any guidance.
The answer I tell myself is NO.
BLFS had good earnings and gave good guidance.
AmerisourceBergen is my top buyout pick.
And I think it was Cold as Ices as well.
Interesting times.
The Kiss of Death returns.
Gang of merry shorts will be here tomorrow.
I believe also there is tremendous upside here also, but like all small biotechs, they are in the clutches of the criminal hedge funds, who are shorting this thing because they need money. Sure would like to see them announce that they are selling IV-Cell to Thermo Fischer, and watch them get fried!
Must have been a memo from the boss to the short crew, for them to hit this this hard on a Sunday. Must be terrified as to what is coming.
Keep up the fight DoGood. I remember them giving it to you that you were nuts about Alan Butler and Stand up to Cancer. And we all know what happened there. I applaud you for your efforts and tenacity.
Best of Luck to you!
I also hear Needham raised their price target to $19.
Not that I want a cap raise, but one at 15 dollars is a lot better than the last one at 2 bucks. Although I bought a lot of stock around 2 dollars.
LOL.
Hyper,
We are on the same page on NWBO, I was being facetious.
Readout there is coming in a couple months.
It will be great news for CYRX, because I believe it will be frontline treatment for GBM, especially with its safety profile.
Then, we have Direct, which is for all solid cancers.
Maybe NWBO will end up buying CYRX.....being facetious again, but the sooner this gets to market, the better for patients, and longs of both stocks.
I have also sold some on this rally.
I don't think anyone thinks NWBO will be approved or successful, (except for me, H2R and hyper), and maybe you, hence the share price of around a quarter. The risk reward is off the charts. Maybe the law of averages says it is time for you to be right. I'm betting on it!
GLTU
H2R,
I have heard Roth Capital partners raised their price target to $22 dollars with the news out of the EMU.
Also, Cyrx does ship for NWBO.
I would love for that to be approved, as my boat is loaded.
We will know in a short while on NWBO
GLTU
I see the loser is back with his band of merry shorts.
Hyper,
I would concur with that speculation, plus positive analyst reports on the company. It is a great day for the terminally ill!
Just like the last meeting with Deutsche Bank, and that subsequent downdraft?
Have to agree. I don't think these guys, especially Shelton, have yet earned the ridiculous amount of shares he got the last time. He can't even give guidance, and we are supposed to cough up over 3.7 million shares again. Seriously?
I do agree with you though on Dendritic Cells....They are the key to immunotherapy.
My Vote:
1. Yes
2. No
3. No
If two is approved it will bring authorized shares to 2.2 Billion.
That is ridiculous. Without 2 being approved, authorized shares will be 1.6 Billion. That is plenty, IMO. If they want more, ask again.
I will say the market was taken by surprise by Celator, CPXX.
Stock would go to $2.00 or 2.50, then right back. Then BOOM! There was a lot of hand wringing on that board too. Just Sayin'.
I would think he still needs 207 million, plus one share.
It seems you are the one doing the spinning with no proof.
Tend to agree....He is the kiss of death!
Count me in that club....
They sure have a lot of pokers in the fire.
I am really curious about the Canadian company Lifelabs, that TBIO signed a contract with over 13 months ago. Would love to know about that one.
Good Luck with that!
Yeah, Yeah...like its going to .17...
One day later you say ut-oh better get in now!
Who is calling the kettle black?
Yes, I did, and may buy some more tomorrow.
Actually got almost 2000 at $.825.
Had an offer for more, but only filled under 2000.
Precipio Announces Q4 2017 Revenue at 350% of Previous Quarter
First post-merger quarter to turn the corner and demonstrate growth
NEW HAVEN, Conn., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces preliminary, unaudited revenues for the 4th quarter of 2017 of approximately $945,000, representing three-fold from the previous quarter of approximately $270,000, as well as a three-fold year-over-year from the 4th quarter of 2016 revenues of approximately $316,000.
2017 Business Integration; 2018 Sales Acceleration
Following the merger with Transgenomic, Inc. in June 2017, we undertook the task of relocating Transgenomic’s laboratory operations to Precipio’s New Haven location, which was completed within 90 days, by the end of the 3rd quarter of 2017. In early October, following a successful migration of all operations, and the training of the necessary staff, Precipio announced the re-opening of its CLIA operations in New Haven. When we resumed operations in October 2017, we were able to retain all customers and quickly refocus on business growth.
“Now that assets have been integrated and systems optimized, we have resumed our focus on sales growth and aggressively capturing market share with our disruptive diagnostic products and services,” commented Ilan Danieli, CEO. “Our team worked around the clock to ensure resumption of services within Q3-2017, and our sales growth in Q4 reflects that hard work. We will remain completely focused on continuing this revenue growth throughout the year.”
Revenue Composition & ICP potential
The majority of revenue was generated by our pathology diagnostic services and various pharma projects handled in our laboratory. Our first ICE-COLD PCR™ (ICP) kit was launched mid-way through Q4-2017, as previously announced, and we were able to quickly convert those products into new customers and revenue.
Although ICP kit sales made up less than 5% of the revenue for this quarter, with our customer, product, and platform expansion, we expect ICP to drive and contribute a significantly larger share of our revenue by year end.
Precipio’s ICP kit, our mutation enrichment technology for liquid biopsies, leads to better cancer outcomes due to the ability to cost effectively test and monitor patients using a simple blood draw instead of an invasive tissue sample. Patients can be frequently tested and monitored for genetic mutations, which may provide an immediate and critical indication of possible treatment responses.
As we continue to release additional ICP panels into the market, those tests will also be available in our CLIA laboratory for direct ordering by physicians and hospitals. Many such hospitals don’t have the necessary facilities to bring those tests in-house, yet they would like to monitor their patients in a rapid, cost-effective manner to identify genetic changes that can help those physicians manage their patient’s treatment.
These customers will be able to now send those tests to Precipio’s CLIA laboratory for immediate and rapid testing and results, generating an additional revenue stream.
Our multi-pronged solution enables hospitals of any size, located anywhere in the world, to either on-board these tests in-house, or use our laboratory to run tests on liquid biopsies, and provide them with this critical information.
Furthermore, we believe that with the increased variability of platforms upon which ICP can be utilized (including Next Generation Sequencing), other segments such as pharmaceutical and clinical trial customers (such as CROs) will become substantial potential users of ICP within their business, generating additional revenue from the continuous commercialization of ICP.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
http://client.irwebkit.com/precipiodx/pr
Precipio Enters Japanese Liquid Biopsy Market with First Hospital Sale
First ICE-COLD PCR™ order generated from distribution partnership with Sowa Trading Company
NEW HAVEN, Conn., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces its entry into the Japanese market with a first order of its ICE-COLD PCR™ (ICP) kit, Precipio’s mutation enrichment technology for liquid biopsies.
ICP leads to better cancer outcomes due to the ability to frequently and cost effectively test and monitor patients for genetic mutations which indicate various treatment responses, using a simple blood draw instead of an invasive tissue sample.
The adoption of liquid biopsies is expected to revolutionize cancer care, with an estimated market of $26B annually. While the US had 1.7 million new cancer patients in 2017, in Asia there were approximately 5 million new cancer patients.
Japan Liquid Biopsy Market
As the largest healthcare spender in Asia, with approximately 8,000 hospitals and over a million new cancer patients each year, we expect Japan to be a substantial regional contributor to our growth in Asia, alongside China & India.
Currently, Precipio’s ICP kits enrich mutations relevant to lung, colon and breast cancer, representing over 30% of those patients. Assuming a regime of four tests per year to monitor a patient with one of those three cancer types alone, a hospital treating 250 cancer patients can generate revenues of $100,000 per year.
This equates to a $120M market opportunity in Japan. By the end of 2018, with our expansion to additional platforms such as NGS, as well as the broadening of our panels to include mutations relevant to additional cancer types, we expect that the market potential can double.
In recent years, lung cancer has surpassed stomach cancer as the leading cause among cancer deaths in Japan. Therefore, Precipio’s first targeted enrichment kit that identifies mutations in lung cancer is an ideal product to introduce into the Japanese market. Utilizing our proprietary ICE-COLD PCR™ technology, the kit will enable Japanese physicians and laboratories to offer the most cost effective resistance mutation test available on the market, tested on blood (liquid) biopsies.
Lung cancer patients can especially benefit from the test which will enable physicians to monitor their patients for resistance to therapies, providing an early-detection solution critical to successful cancer treatment. Laboratories that have any of the platforms on which ICP works will be able to quickly set up the assay with no capital expenditures.
“We see significant value in the ICE COLD-PCR™ technology and the ICEme Kits and are excited that we have received our first order from one of our large hospital customers. We believe the ICP technology will enable many of our hospital customers to cost effectively run liquid biopsy testing in their own labs,” says Susumu Kuwashima, President, Sowa Trading Co., Inc.
ICP Sales Plan
Once a hospital has set up ICP in its laboratory and begins offering the test to its patients, it becomes a recurring customer who continues to purchase Precipio’s ICP kits. Since most hospitals treat multiple types of cancer, as our product offering expands, those new kits will immediately be adopted by the hospital to broaden its offering to other cancer patients.
Precipio expects to grow its business by increasing its hospital laboratory customer base. Our plan calls for the addition of 25-50 new hospital customers in 2018, with approximately 25% of those hospitals outside of the US. With multiple new ICP kits expected to be launched in 2018 broadening the type of cancers for which these mutations are relevant, we expect each hospital to generate revenue of between $50,000-$250,000 annually, depending on the size of the hospital.
“We’re pleased to see the continued progress of our ICE COLD-PCR™ kit adoption globally,” said Ilan Danieli, Precipio CEO. “We believe Japan has significant potential for liquid biopsy testing and are excited to have our first Japanese hospital, successfully on-boarded by Sowa. ICE COLD-PCR™ enables hospital customers in Japan an opportunity to offer liquid biopsy testing in their own laboratories, providing improved monitoring and care to their patients.”
About Sowa Trading Company
Sowa Trading Co., Inc. was founded in October 1984 by a group of engineers as a merger partner of Japan in order to distribute the scientific instrumentation in the Japanese market. Sowa invested in Packard Japan KK a subsidiary of Packard Bioscience Company (United States), which is the world’s largest radiation analysis manufacturer. For over 30 years, Sowa has been introducing the latest laboratory instruments and reagents from Western countries to Japanese researchers of life sciences and environmental sciences. Sowa will continuously import the most advanced instruments in the world, which is necessary to the research of not only environmental sciences but also life sciences, and further contribute to Japan’s research development and science technology sectors.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
http://client.irwebkit.com/precipiodx/pr
That will be very tough....
Daniel-San, if you are correct, I hope it is with Deutsche Bank.
Wow, then to the moon alice, is not a pump...please.
You wonder why NWBO is silent. Every time they speak, this bald headed liar pulls $hit out of his a$$, acting like he knows something. He should look in the mirror when asking who the SEC should shut down.